Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes. The data were presented during the late-breaking trials session at PCR London Valves 2022. Patients enrolled in the TRISCEND study had symptomatic moderate or greater functional or degenerative tricuspid regurgitation (TR), despite optimal medical therapy.

The TRISCEND study enrolled 176 patients, representing the dataset among transcatheter tricuspid valve replacement therapies. Following positive 30-day and 6-month results, the one-year outcomes demonstrated: High survival of 90.1% and high freedom from heart failure hospitalization at 88.4%; Significant and sustained TR reduction, with 97.6% of patients with mild or trace TR (n=84); Significantly improved functional and quality-of-life outcomes, with 93% of patients in NYHA Class I or II compared to 26% at baseline (n=89) and a 26-point increase in KCCQ score over baseline (n=102).